FEATURED/ARCHIVES (05/05/24)
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee · February 2022
Publications (Books-Reports)
NCBI>Neurology
OROS-Methylphenidate to Reduce ADHD Symptoms in Male Prisoners Aged 16-25 Years: A RCT · July 2022
Publications (Books-Reports)
National Institute for Health and Care Research
Quetiapine for Major Depressive Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines · February 2020
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Methadone Treatment for Opioid Use Disorder – Improving Access through Regulatory and Legal Change: Proceedings of a Workshop (Meetings-Events) · July 2022
Publications (Books-Reports)
National Academies Press
Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder · July 2022
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Bupropion for Treatment Resistant Depression · April 2021
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Ketamine for Adults with Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update · January 2024
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics (Disruptive Psychopharmacology) · March 2022
Publications (Chapters)
NCBI>Current Topics in Behavioral Neurosciences
Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines · February 2020
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Practical Tools for Prescribing and Promoting Buprenorphine in Primary Care Settings · December 2021
Publications (Books-Reports)
Substance Abuse and Mental Health Services Administration
Fluoxetine to Improve Functional Outcomes in Patients After Acute Stroke: The FOCUS RCT · May 2020
Publications (Books-Reports)
National Institute for Health Research
Monitoring Patients with Psychotic Disorders for Clozapine-Induced Myocarditis or Cardiomyopathy · June 2022
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia) · April 2021
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health